Obesity PSPs in KSA: Designing for Long-Term Patient Adherence

Saudi Arabia faces one of the most significant obesity burdens in the world. According to the Saudi Health Information Center, more than 35% of Saudi adults are classified as obese, with obesity-related complications — type 2 diabetes, cardiovascular disease, and musculoskeletal disorders — placing substantial strain on the Kingdom's healthcare system. Vision 2030's national health targets explicitly include reducing the prevalence of obesity and its comorbidities.

Against this backdrop, the arrival of GLP-1 receptor agonists as approved therapies for chronic weight management has created a genuine inflection point. Brands that successfully launch these therapies in KSA will not win solely on clinical efficacy data — they will win on patient experience. And patient experience in chronic disease management lives or dies by the quality of the patient support program (PSP) behind the therapy.

This article examines what it takes to design and operate an obesity PSP that delivers meaningful adherence outcomes in the Saudi Arabian market, with specific attention to cultural fit, operational infrastructure, and regulatory compliance.

Many international pharma companies arrive in Saudi Arabia with PSP frameworks designed for European or North American patient populations. These templates typically assume: high health literacy, familiarity with structured patient navigation, comfort with digital self-monitoring tools, and proactive patient self-advocacy. In KSA, the patient reality is more complex.

Saudi patients with obesity often face significant stigma — both societal and within the healthcare system — that shapes how openly they engage with support programs. Family involvement in healthcare decisions is the norm rather than the exception, and any PSP that does not account for family dynamics will struggle to achieve the engagement levels it projects. Additionally, Saudi patients demonstrate high trust in their treating physician, meaning that PSP messaging that appears disconnected from — or inconsistent with — what the doctor has communicated will lose credibility quickly.

Effective PSPs in KSA must be designed around these realities from the ground up, not adapted from international templates as an afterthought.

Patient Onboarding and Activation

The first 30 to 90 days of a new therapy are critical for long-term adherence. PSP onboarding for obesity therapies must accomplish several goals simultaneously: establish realistic expectation-setting around weight loss trajectories (GLP-1 therapies produce meaningful but non-linear weight loss, and many patients discontinue early when expectations are unmet), educate on injection technique and side effect management, and build the behavioral habits — dietary changes, activity tracking, regular weigh-ins — that maximize therapeutic outcomes.

In KSA, onboarding works most effectively when it includes a human touchpoint — a nurse educator, patient coordinator, or pharmacist counselor — rather than relying exclusively on digital self-enrollment. Patients report higher program satisfaction and lower early dropout when they have interacted with a real person who answered their initial questions.

Onboarding materials should be available in Arabic as the primary language, with culturally appropriate dietary guidance that accounts for traditional Saudi cuisine, fasting during Ramadan, and social eating patterns around iftar and suhoor.

Ongoing Behavioral Coaching and Remote Monitoring

Adherence to obesity therapies is not a static state — it is a behavior that must be continuously reinforced. PSPs that check in at enrolment and then disappear until the 12-month mark will see high dropout rates. Effective ongoing support for obesity patients in KSA should include:

Regular check-in touchpoints: Monthly calls or messages from a dedicated nurse or patient coordinator, calibrated to the patient's preferences and digital comfort level. WhatsApp-based check-ins have shown strong engagement in the KSA context, provided they are implemented within a PDPL-compliant framework with explicit patient consent.

Weight and symptom tracking tools: Simple, Arabic-language mobile tools or structured call-in options for patients who are less digitally engaged. The goal is data continuity — knowing when a patient is struggling before they silently discontinue.

Side effect management pathways: GLP-1 therapies frequently produce gastrointestinal side effects, particularly during dose escalation. PSPs that have a clear, accessible pathway for patients to report side effects and receive guidance — without requiring a full clinic appointment — demonstrate tangible value and prevent therapy abandonment over manageable symptoms.

Ramadan-Specific Protocols

Any PSP operating in KSA must have a Ramadan protocol. Fasting during Ramadan presents specific challenges for patients on obesity therapies: injection timing relative to iftar and suhoor, managing appetite suppression during a period with strong cultural expectations around communal eating, and navigating the psychological relationship with food in a context laden with social and spiritual significance.

PSPs that proactively reach out to enrolled patients ahead of Ramadan, provide tailored guidance co-developed with an endocrinologist or nutritionist, and offer increased touchpoint frequency during the holy month will see measurably better adherence compared to programs that treat Ramadan as an invisible variable.

Family Engagement Modules

As noted above, Saudi patients rarely make healthcare decisions in isolation. Spouses, parents, and adult children are frequently involved in treatment conversations. PSPs that provide family-oriented education — what to expect during the patient's weight loss journey, how family members can support dietary changes, and how to navigate social eating occasions — are meeting a genuine patient need that standard PSPs ignore.

This does not require elaborate infrastructure: a well-designed family information booklet, a brief educational session offered at onboarding, and a named contact for family members with questions can meaningfully shift the social environment around the patient's therapy.

HCP Connectivity and Closed-Loop Reporting

The most sophisticated obesity PSPs in KSA are those that maintain a real-time connection between the patient support program and the treating physician. This means regular reporting to HCPs on enrolled patients' engagement levels, flag systems when a patient has missed check-ins or reported a side effect, and clear escalation pathways for clinical concerns.

HCPs who receive structured updates from the PSP about their patients' progress are more likely to reinforce program participation at clinic visits, creating a virtuous cycle of engagement. Conversely, PSPs that operate as invisible black boxes between HCP and patient miss an opportunity to embed the program into the therapeutic relationship.

Regulatory note: All patient data collected and shared within a PSP must comply with the Personal Data Protection Law (PDPL). Patient consent for data collection, processing, and sharing with HCPs must be explicit, documented, and accessible for audit. PSP operators should also ensure that any nurse or pharmacist activities within the program are conducted within the scope of practice permitted by the Saudi Commission for Health Specialties (SCFHS) and relevant licensing bodies.

Many brands measure PSP performance through enrolment volume alone — a metric that tells you almost nothing about whether the program is delivering value. The metrics that matter for obesity PSPs in KSA are:

90-day persistence rate: What percentage of enrolled patients are still on therapy at 90 days? This is the critical early adherence window for GLP-1 therapies.

12-month continuation rate: The benchmark that predicts long-term clinical outcomes and brand value demonstration.

Weight loss outcomes at 6 months: Aggregate, anonymized patient outcome data not only demonstrates program efficacy but provides powerful real-world evidence for HCP engagement.

Patient-reported satisfaction (NPS or equivalent): A simple, structured satisfaction measure that identifies program elements to strengthen and weaknesses to address.

HCP satisfaction and engagement: Do referring physicians find the program valuable? Are they seeing their patients return to clinic with better outcomes?

Saudi Arabia's obesity treatment market will grow substantially over the next five years as new therapies gain SFDA approval and prescribing infrastructure develops. Brands that invest now in building culturally intelligent, operationally robust PSPs will establish a durable competitive advantage that cannot be easily replicated by late entrants.

The cost of a well-designed PSP is dwarfed by the commercial value of even a 10% improvement in 12-month persistence rates. The brands that understand this will define the obesity market in KSA — those that treat PSPs as a compliance checkbox will cede that ground.

Spectra Solutions MEA designs and operationalizes patient support programs for pharma brands across KSA and the GCC. To discuss your obesity PSP or broader patient activation strategy, contact us at service@spectra-mea.com.